These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 11060699

  • 1. Ebselen: prospective therapy for cerebral ischaemia.
    Parnham M, Sies H.
    Expert Opin Investig Drugs; 2000 Mar; 9(3):607-19. PubMed ID: 11060699
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
    Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM.
    Br J Pharmacol; 1997 Nov; 122(6):1251-6. PubMed ID: 9401794
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The early research and development of ebselen.
    Parnham MJ, Sies H.
    Biochem Pharmacol; 2013 Nov 01; 86(9):1248-53. PubMed ID: 24012716
    [Abstract] [Full Text] [Related]

  • 8. Ebselen, a selenoorganic compound as glutathione peroxidase mimic.
    Sies H.
    Free Radic Biol Med; 1993 Mar 01; 14(3):313-23. PubMed ID: 8458589
    [Abstract] [Full Text] [Related]

  • 9. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial.
    Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, Yasuhara H.
    Cerebrovasc Dis; 1999 Mar 01; 9(2):112-8. PubMed ID: 9973655
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
    Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, Kikuchi H, Ohta T, Ishibashi S.
    Neurosurgery; 1998 Feb 01; 42(2):269-77; discussion 277-8. PubMed ID: 9482177
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells.
    Yoshizumi M, Kogame T, Suzaki Y, Fujita Y, Kyaw M, Kirima K, Ishizawa K, Tsuchiya K, Kagami S, Tamaki T.
    Br J Pharmacol; 2002 Aug 01; 136(7):1023-32. PubMed ID: 12145102
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury.
    Tunc T, Uysal B, Atabek C, Kesik V, Caliskan B, Oztas E, Ersoz N, Oter S, Guven A.
    J Surg Res; 2009 Aug 01; 155(2):210-6. PubMed ID: 19505699
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ebselen pretreatment attenuates ischemia/reperfusion injury and prevents hyperglycemia by improving hepatic insulin signaling and β-cell survival in gerbils.
    Park S, Kang S, Kim DS, Shin BK, Moon NR, Daily JW.
    Free Radic Res; 2014 Aug 01; 48(8):864-74. PubMed ID: 24807533
    [Abstract] [Full Text] [Related]

  • 20. Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats.
    Wasser S, Lim GY, Ong CN, Tan CE.
    J Gastroenterol Hepatol; 2001 Nov 01; 16(11):1244-53. PubMed ID: 11903743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.